Pharmadigm, Inc.

Pharmadigm, a privately held US Corporation, is engaged in the discovery and development of novel therapeutics for use by acute care institutions in the management of acute inflammation. The Company currently has two products in development. The first, PB008, an injectable formulation of dehydroepiandrosterone sulfate (DHEAS), is in Phase II clinical testing in the United States to evaluate its utility in the management of acute asthmatic episodes and severe burns. The second, PB007, an injectable formulation of dehydroepiandrosterone (DHEA), is currently undergoing animal pharmacology/toxicology testing having successfully completed animal efficacy trials in well-accepted models of heart attack and stroke. Pharmadigm has a worldwide exclusive license from the University of Utah Research Foundation to commercialize its technology and an extensive intellectual property portfolio consisting of issued and pending US and foreign patents, proprietary formulations and screening assays. Since inception in 1991, Pharmadigm's investors have provided over $25 million in private and venture capital.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: